News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
US & Canada
Post an Event
News | News By Subject | News by Disease |
News By Date | Search News
ARC Linkage Grant to Support Patrys Limited (PAB.AX)' Partnership With Macquarie University for Development of Cancer Diagnostics
7/10/2013 9:21:13 AM
Get the latest biotech news where you want it. Sign up for the free
GenePool newsletter today!
Melbourne, Australia; 10 July, 2013: Patrys Limited (ASX: PAB), a clinical stage biotechnology company, announced today that scientific collaborators at Macquarie University (Macquarie), Sydney, have been awarded a $427,510 Australian Government grant to support the development of new highly sensitive, non-invasive cancer diagnostic kits using Patrys’ lead candidate PAT-SM6.
PAT-SM6 is an IgM antibody that has successfully completed a Phase I trial in melanoma and is currently in a Phase I/IIa trial for patients with relapsed or refractory multiple myeloma.
The grant, which has been awarded by the Australian Research Council (“ARC”), will bring together experts from Macquarie led by Dr. Dayong Jin, Professor Nicolle Packer, Professor James Piper, Associate Professor Robert Willows and Professor Simon Foote with industry partners Minomic International Limited and Patrys.
The project will combine Macquarie’s new Super Dot nanocrystal technology with Minomic’s and Patrys’ antibodies directed against prostate and multiple myeloma cancer biomarkers, respectively.
Patrys’ previous collaboration with Professor Packer showed that PAT-SM6 detects specific changes in the proteins present on the surface of multiple myeloma cells, but not on normal cells. These cancer-modified cells in the patients’ blood and urine are very rare in early stages of disease and their detection poses a “needle-in-a-haystack” challenge at both the research and clinical levels. Current diagnostic tests are not sensitive enough to detect these rare-event cells, resulting in an inefficient early detection and diagnosis of cancer and consequently poor prognosis.
Dr. Jin and colleagues from Macquarie University have developed highly sensitive technologies using super-bright nanocrystals that will enable the detection of single abnormal cells in body fluids, and will provide the basis for new, sensitive and non-invasive, early-stage screening of multiple myeloma, prostate cancer and other malignancies.
Patrys CEO, Dr. Marie Roskrow, said: “Patrys is very proud to be part of this exciting and cutting-edge project and welcomes the opportunity to explore the innovative aspects of Patrys’ antibodies. The possibility to use Patrys’ antibodies as cancer diagnostics as well as therapeutics is very exciting and potentially brings additional opportunities and value to the Patrys’ pipeline.”
For further information, please contact:
Dr. Marie Roskrow
Chief Executive Officer
P: +61 3 9670 3273
P: 0417 382 391
P: +61 3 9866 4722
About Patrys Limited:
Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of natural human antibodies as therapies for cancer. Patrys has a deep pipeline of anti-cancer natural human antibodies that enable both internal development and partnering opportunities. More information can be found at www.patrys.com.
The natural human antibody PAT-SM6 has been shown to have potent anti-cancer properties in a large number of laboratory and animal studies. More specifically, Patrys has now screened PAT-SM6 against more than 200 tumours from individual patients with various cancers, and the product binds to over 90% of the tumours screened regardless of cancer type or patient age, gender or disease stage. With respect to multiple myeloma PAT-SM6 has shown particularly strong promise. Patrys has filed patent applications to cover the PAT-SM6 antibody molecule, disease target, and the mechanism of action. Patrys has successfully completed a Phase I clinical trial to evaluate PAT-SM6 as a therapy for melanoma. In November 2012, Patrys commenced a PAT-SM6 clinical trial in patients with multiple myeloma. Multiple myeloma is a type of bone marrow cancer that affects approximately 1,200 Australians each year with 39% five-year survival rate.
Help employers find you! Check out all the jobs and post your resume.